Candel Therapeutics (CADL) Income towards Parent Company: 2020-2024
Historic Income towards Parent Company for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$30.2 million.
- Candel Therapeutics' Income towards Parent Company rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
- Candel Therapeutics' Income towards Parent Company amounted to -$30.2 million in FY2024, which was up 10.44% from -$33.7 million recorded in FY2023.
- In the past 5 years, Candel Therapeutics' Income towards Parent Company ranged from a high of -$13.7 million in FY2020 and a low of -$35.2 million during FY2022.
- In the last 3 years, Candel Therapeutics' Income towards Parent Company had a median value of -$33.7 million in 2023 and averaged -$33.0 million.
- Per our database at Business Quant, Candel Therapeutics' Income towards Parent Company crashed by 88.18% in 2021 and then grew by 10.44% in 2024.
- Candel Therapeutics' Income towards Parent Company (Yearly) stood at -$13.7 million in 2020, then plummeted by 88.18% to -$25.8 million in 2021, then tumbled by 36.59% to -$35.2 million in 2022, then grew by 4.25% to -$33.7 million in 2023, then rose by 10.44% to -$30.2 million in 2024.